BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 172 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,089,838 | +104.3% | 130,676 | +181.2% | 0.04% | +40.0% |
| Q4 2022 | $533,567 | -22.8% | 46,478 | -15.3% | 0.02% | +13.6% |
| Q3 2022 | $691,000 | +9.0% | 54,871 | -6.4% | 0.02% | +22.2% |
| Q2 2022 | $634,000 | -31.2% | 58,645 | +4.7% | 0.02% | 0.0% |
| Q1 2022 | $921,000 | +22.8% | 56,014 | +3.0% | 0.02% | +20.0% |
| Q4 2021 | $750,000 | -20.1% | 54,383 | -16.7% | 0.02% | -16.7% |
| Q3 2021 | $939,000 | +15.6% | 65,312 | +24.6% | 0.02% | +38.5% |
| Q2 2021 | $812,000 | +49.8% | 52,412 | -3.4% | 0.01% | +30.0% |
| Q1 2021 | $542,000 | -15.8% | 54,272 | -36.8% | 0.01% | -28.6% |
| Q4 2020 | $644,000 | +69.9% | 85,880 | -13.2% | 0.01% | +16.7% |
| Q3 2020 | $379,000 | +56.6% | 98,949 | +103.3% | 0.01% | +33.3% |
| Q2 2020 | $242,000 | – | 48,675 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 6,071,142 | $38,430,000 | 18.43% |
| RTW INVESTMENTS, LP | 4,078,895 | $25,819,000 | 9.72% |
| VHCP Management, LLC | 1,155,104 | $7,312,000 | 7.86% |
| RA Capital Management | 2,989,795 | $18,925,000 | 2.68% |
| DLD Asset Management, LP | 1,258,700 | $7,967,000 | 2.61% |
| Avoro Capital Advisors LLC | 1,631,502 | $10,327,000 | 2.09% |
| Ghost Tree Capital, LLC | 1,150,000 | $7,280,000 | 1.75% |
| GREAT POINT PARTNERS LLC | 725,000 | $4,589,000 | 0.94% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,237,734 | $20,495,000 | 0.84% |
| Baker Brothers Advisors | 10,963,944 | $69,402,000 | 0.68% |